Related Experiment Video

Updated: May 17, 2026

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

Cholesterol metabolism and resistance to tamoxifen

Marc Poirot1, Sandrine Silvente-Poirot, Ralph R Weichselbaum

  • 1UMR 1037 INSERM-University Toulouse III, Cancer Research Center of Toulouse, Toulouse, France. marc.poirot@inserm.fr

Current Opinion in Pharmacology
|October 16, 2012
PubMed

Insights

The oncoprotein MUC-1 promotes Tamoxifen resistance in breast cancer by altering cholesterol and lipid metabolism. Targeting these metabolic pathways may improve Tamoxifen therapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The oncoprotein MUC-1 is implicated in breast cancer progression.
  • Tamoxifen (Tam) is a standard endocrine therapy for estrogen receptor-positive breast cancer.
  • Tamoxifen resistance is a significant clinical challenge.

Purpose of the Study:

  • To investigate the role of MUC-1 in Tamoxifen resistance.
  • To explore the connection between MUC-1, cholesterol, and lipid metabolism in breast cancer.
  • To identify potential new therapeutic targets for overcoming Tamoxifen resistance.

Main Methods:

  • Analysis of gene transcription related to cholesterol and lipid metabolism in breast cancer tumors.
  • Correlation studies between MUC-1 expression and Tamoxifen resistance.
  • Review of molecular mechanisms underlying Tamoxifen action and resistance.

Main Results:

  • MUC-1 upregulates genes involved in cholesterol and lipid metabolism.
  • MUC-1 expression correlates with Tamoxifen resistance, even with estrogen receptor α presence.
  • Molecular studies suggest cholesterol metabolism pathways are key to Tamoxifen's effects.

Conclusions:

  • Cholesterol and lipid metabolism are critical factors in Tamoxifen's therapeutic efficacy.
  • MUC-1-driven metabolic alterations contribute to Tamoxifen resistance.
  • Targeting cholesterol and lipid metabolism presents a potential strategy to enhance Tamoxifen treatment.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...